Scadden David's Form 4 filing
Agios Pharmaceuticals, Inc. (AGIO) · filed Oct 10, 2025
- Accession no.
- 0001439222-25-000108
- Filed
- Oct 10, 2025
- Trade date
- Oct 8, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $8.20K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Scadden DavidCIK 0001707715 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2025 | Common stock | MOption exerciseAcquired | +200 | $18.09 | +$3,618 | 17,803 | Direct | |
| Oct 8, 2025 | Common stock | SSaleDisposed | −200 | $41.00 | −$8,200 | 17,603 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2025 | Common stock | MOption exerciseDisposed | −200 | $0.00 | $0 | 27,107 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.